. 2021 Jun 2;10(7):667–675. doi: 10.1530/EC-21-0087
This work is licensed under a Table 1.
Clinical characteristics of the participants according to serum AT3 activity quartiles.
| Variables | Total | Q1 | Q2 | Q3 | Q4 | P for trend |
|---|---|---|---|---|---|---|
| AT3 activity (%) (range) | 92.07 ± 16.92 (38.60–143.90) | 71.35 ± 6.41 (38.60–79.70) | 85.55 ± 3.34 (79.71–91.15) | 97.08 ± 3.60 (91.16–103.77) | 114.36 ± 9.13 (103.78–143.90) | <0.001 |
| n | 1612 | 405 | 401 | 403 | 403 | – |
| Age (years) | 58.67 ± 13.09 | 62.19 ± 13.28 | 58.08 ± 12.75 | 57.59 ± 13.26 | 56.81 ± 12.41 | <0.001 |
| Male, n (%) | 898 (55.7) | 226 (55.8) | 225 (56.1) | 217 (53.8) | 230 (57.1) | 0.826 |
| BMI (kg/m2) | 25.80 ± 3.52 | 25.75 ± 3.54 | 25.99 ± 3.42 | 26.02 ± 3.68 | 25.36 ± 3.39 | 0.076 |
| SBP (mmHg) | 136.8 ± 18.02 | 136.5 ± 17.9 | 136.4 ± 17.9 | 138.5 ± 18.28 | 135.7 ± 17.9 | 0.165 |
| DBP (mmHg) | 79.3 ± 10.9 | 78.2 ± 10.9 | 79.3 ± 11.6 | 80.64 ± 11.0 | 79.3 ± 9.9 | 0.016 |
| Diabetes duration (years) | 6 (1–10) | 6 (1–10) | 6 (2–10) | 5 (2–10) | 5 (1–10) | 0.108 |
| Glucose-lowering therapies | ||||||
| Lifestyle alone, n (%) | 132 (8.2) | 8 (2.0) | 16 (4.0) | 37 (9.2) | 71 (17.6) | <0.001 |
| Insulin treatments, n (%) | 869 (53.9) | 226 (55.8) | 227 (56.6) | 206 (51.1) | 210 (52.1) | 0.314 |
| Insulin-secretagogues, n (%) | 857 (53.2) | 227 (56.0) | 203 (50.6) | 204 (50.6) | 223 (55.3) | 0.240 |
| Metformin, n (%) | 933 (57.9) | 227 (56.0) | 209 (52.1) | 264 (65.5) | 233 (57.8) | 0.001 |
| Pioglitazone, n (%) | 594 (36.8) | 166 (41.0) | 156 (38.9) | 132 (32.8) | 140 (34.7) | 0.061 |
| AGIs, n (%) | 424 (26.3) | 131 (32.3) | 105 (26.2) | 102 (25.3) | 86 (21.3) | 0.005 |
| GLP-1RAs, n (%) | 54 (3.3) | 12 (3.0) | 17 (4.2) | 15 (3.7) | 10 (2.5) | 0.517 |
| DPP-4Is, n (%) | 456 (28.3) | 102 (25.2) | 101 (25.2) | 128 (31.8) | 125 (31.0) | 0.053 |
| Hypertension, n (%) | 823 (51.1) | 223 (55.1) | 211 (52.6) | 197 (48.9) | 192 (47.6) | 0.131 |
| TG (mmol/L) | 1.85 (1.20–2.96) | 1.65 (1.07–2.75) | 1.87 (1.27–2.84) | 2.02 (1.24–3.03) | 1.89 (1.22–3.18) | 0.008 |
| TC (mmol/L) | 4.51 ± 1.17 | 4.31 ± 0.96 | 4.42 ± 1.03 | 4.65 ± 1.42 | 4.67 ± 1.20 | <0.001 |
| HDL-C (mmol/L) | 1.03 ± 0.27 | 0.99 ± 0.25 | 0.99 ± 0.27 | 1.04 ± 0.27 | 1.09 ± 0.29 | <0.001 |
| LDL-C (mmol/L) | 2.56 ± 0.80 | 2.40 ± 0.71 | 2.49 ± 0.70 | 2.65 ± 0.78 | 2.69 ± 0.95 | <0.001 |
| Scr (umol/L) | 59.14 ± 22.14 | 61.48 ± 19.26 | 59.27 ± 25.43 | 56.21 ± 19.14 | 59.57 ± 23.80 | 0.010 |
| HbA1c (%) | 9.21 ± 2.08 | 9.09 ± 1.96 | 9.14 ± 2.14 | 9.25 ± 1.97 | 9.34 ± 2.25 | 0.330 |
| PT (s) | 11.83 ± 0.95 | 12.31 ± 1.06 | 11.87 ± 0.72 | 11.67 ± 0.84 | 11.46 ± 0.95 | <0.001 |
| APTT (s) | 30.01 ± 5.82 | 31.88 ± 6.49 | 30.38 ± 5.20 | 29.76 ± 5.67 | 28.02 ± 5.15 | <0.001 |
| Fg (g/L) | 2.62 ± 0.84 | 2.60 ± 0.94 | 2.59 ± 0.83 | 2.55 ± 0.78 | 2.74 ± 0.76 | 0.009 |
| lnHOMA-IR | 1.39 ± 0.88 | 1.60 ± 0.85 | 1.46 ± 0.88 | 1.36 ± 0.89 | 1.15 ± 0.84 | <0.001 |
| lnISIMatsuda | 4.05 ± 0.70 | 3.86 ± 0.67 | 3.99 ± 0.71 | 4.08 ± 0.69 | 4.28 ± 0.67 | <0.001 |